Page last updated: 2024-09-03

esonarimod and bucillamine

esonarimod has been researched along with bucillamine in 2 studies

Compound Research Comparison

Studies (esonarimod)	Trials (esonarimod)	Recent Studies (post-2010) (esonarimod)	Studies (bucillamine)	Trials (bucillamine)	Recent Studies (post-2010) (bucillamine)
33	1	8	193	11	33

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fukushima, K; Inoue, T; Takeshita, K	1
Inoue, T; Nakaike, S; Sugimoto, M; Takeshita, K; Yamashita, M	1

Other Studies

2 other study(ies) available for esonarimod and bucillamine

Article	Year
Effects of KE-758; an active metabolite of the new anti-rheumatic drug KE-298, D-penicillamine, bucillamine and auranofin on the proliferation of murine lymphocytes, and the production of nitric oxide by murine macrophages. International immunopharmacology, 2001, Volume: 1, Issue:5 Topics: Animals; Antirheumatic Agents; Auranofin; Cell Division; Cell Line; Concanavalin A; Cysteine; Female; Hydrogen Peroxide; In Vitro Techniques; Interferon-gamma; Ionomycin; Lipopolysaccharides; Lymphocyte Activation; Lymphocytes; Macrophages; Mice; Mice, Inbred DBA; Nitric Oxide; Penicillamine; Phenylpropionates; Recombinant Proteins; Tetradecanoylphorbol Acetate	2001
KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Drugs under experimental and clinical research, 2002, Volume: 28, Issue:5 Topics: Antirheumatic Agents; Auranofin; Cell Line; Cysteine; Enzyme-Linked Immunosorbent Assay; Humans; Interferon-gamma; Interleukin-1; Lipopolysaccharides; Monocytes; Penicillamine; Phenylbutyrates; Phenylpropionates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha	2002

Article

Year

Effects of KE-758; an active metabolite of the new anti-rheumatic drug KE-298, D-penicillamine, bucillamine and auranofin on the proliferation of murine lymphocytes, and the production of nitric oxide by murine macrophages.

International immunopharmacology, 2001, Volume: 1, Issue:5

Topics: Animals; Antirheumatic Agents; Auranofin; Cell Division; Cell Line; Concanavalin A; Cysteine; Female; Hydrogen Peroxide; In Vitro Techniques; Interferon-gamma; Ionomycin; Lipopolysaccharides; Lymphocyte Activation; Lymphocytes; Macrophages; Mice; Mice, Inbred DBA; Nitric Oxide; Penicillamine; Phenylpropionates; Recombinant Proteins; Tetradecanoylphorbol Acetate

2001

KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line.

Drugs under experimental and clinical research, 2002, Volume: 28, Issue:5

Topics: Antirheumatic Agents; Auranofin; Cell Line; Cysteine; Enzyme-Linked Immunosorbent Assay; Humans; Interferon-gamma; Interleukin-1; Lipopolysaccharides; Monocytes; Penicillamine; Phenylbutyrates; Phenylpropionates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha

2002